Home > Gastroenterology > UEGW 2019 > Inflammatory Bowel Disease > Ustekinumab is safe and effective in ulcerative colitis: 2-year data

Ustekinumab is safe and effective in ulcerative colitis: 2-year data

Presented By
Prof. Bruce Sands, Icahn School of Medicine at Mount Sinai, New York, USA
Conference
UEGW 2019
Trial
Phase 3, UNIFI
New 2-year data from the long-term extension of the phase 3 UNIFI study demonstrates the efficacy and safety of ustekinumab through 2 years of treatment in adults with moderately to severely active ulcerative colitis (UC). These data, presented by Prof. Bruce Sands (Icahn School of Medicine at Mount Sinai, New York, USA) as a late-breaking data abstract [1], included 399 participants who were in clinical response 8 weeks after receiving a single intravenous (IV) induction dose of ustekinumab and who were then randomised to receive ustekinumab subcutaneous (SC) 90 mg injections every 12 weeks (q12w), ustekinumab SC 90 mg injections every 8 weeks (q8w), or placebo, and who were treated in the long-term extension. Results showed that the majority of patients were able to sustain remission through week 92 as assessed by symptomatic remission. The percentage of patients receiving ustekinumab SC who were in symptomatic remission between weeks 44 and 92 ra...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on